Lung Cancer Clinical Trial
This study will evaluate a new imaging technology, termed optical frequency domain imaging (OFDI) for detecting and diagnosing pulmonary malignancy in the central airways.
The prevalence and high mortality rate associated with lung squamous cell carcinoma and the
lack of any widely accepted screening and surveillance tools, highlights the need for new
imaging paradigms that will ultimately lead to a reduction in patient mortality.
Bronchial carcinoma-in-situ will progress to invasive cancer in over 40% of individuals, and
although the progression occurs over a long period of time, the majority of carcinomas are
detected in the later stages of disease development, offering patients only a slim chance of
cure. Although significant effort in the development of screening paradigms for the detection
of lung cancer in the central airways have been made, to date there is still no widely
accepted and validated approach. Optical frequency domain imaging (OFDI) is a recent
derivative of optical coherence tomography (OCT). OFDI can be used to conduct volumetric
microscopy of the airways at a resolution comparable with architectural histopathology. The
long term goal of this study is to use OFDI to screen the airways with the hope of detecting
squamous cell carcinoma at an early more curable stage.
Standard of care bronchoscopy preparation and procedures will be followed including moderate
sedation, pulse oximetry and blood pressure monitoring as per department protocol. A
combination of currently approved bronchoscopy techniques including standard white light
bronchoscopy, autofluorescence bronchoscopy, and narrow band imaging will be used to assess
the airways. Bronchial regions of interest (ROI) suspected to be premalignant or malignant,
will be imaged using the OFDI system and catheter prior to biopsy acquisition. It is
anticipated that a minimum of 3 OFDI-biopsy correlated pairs from each study participant will
be obtained. An additional OFDI and biopsy will be obtained from a normal ROI. It is expected
that the experimental procedure will add less than 10 minutes to the total length of the
bronchoscopy procedure, but a stopping rule will be instituted to ensure that the
experimental procedure does not exceed 20 minutes.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|